LAVAL, QC, Feb. 11, 2021 /CNW/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company")
issued the following statement in response to the Schedule 13D
filed by Icahn Capital LP filed earlier today:
Bausch Health's Board of Directors and management team welcome
open communication with our shareholders and constructive input
toward the shared goal of enhancing shareholder value. Our Board of
Directors and management team are committed to acting in the best
interests of the Company and our shareholders. We continually
review the Company's strategic priorities and capital allocation to
evaluate opportunities to maximize long-term shareholder value.
Underscoring this commitment is our previously announced
intention to spin off Bausch + Lomb into an independent
publicly traded entity to unlock what we believe is unrecognized
value in Bausch Health. We remain committed to pursuing all
opportunities and paths forward to deliver value for our
shareholders.
The Company exited 2020 with solid momentum, outperforming the
high end of our guidance by generating revenue that exceeded
$2.2 billion and delivering strong
adjusted EBITDA and cash flows. We remain strategically focused on
executing on our COVID-19 recovery plan, while capitalizing on key
growth drivers and catalysts to grow EBITDA, improve working
capital and delever our Company.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Bausch Health Forward-looking Statements
This news
release may contain forward-looking statements, which may generally
be identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch-health-responds-to-schedule-13d-filing-from-icahn-capital-lp-301227411.html
SOURCE Bausch Health Companies Inc.